Efficacy of OnabotulinumtoxinA for Episodic Migraine Treatment Calls for Further Research

Strategic Insights -

A phase 3 trial, PRECLUDE, investigated the efficacy of onabotulinumtoxinA (onabotA) for preventing episodic migraine, a complex neurological disease characterized by recurring headache attacks. The study involved 775 patients aged 18-65 years, who were randomized to receive placebo, onabotA 155 U, or onabotA 195 U. The trial protocol included a four-week screening phase, a 24-week double-blind phase, and a 24-week open-label extension phase. The primary endpoint was the change in the frequency of monthly migraine days from baseline across months 5 and 6. Results showed that both treatment groups demonstrated a reduction in the frequency of monthly migraine days, but neither group achieved statistically significant improvement compared to the placebo group.

Key Takeaways:

  • The PRECLUDE trial, a phase 3 multicenter randomized double-blind placebo-controlled study, evaluated the efficacy and safety of onabotA for preventing episodic migraine.
  • 775 patients aged 18-65 years were randomized to receive placebo, onabotA 155 U, or onabotA 195 U in a four-week screening phase, a 24-week double-blind phase, and a 24-week open-label extension phase.
  • The primary endpoint was the change in the frequency of monthly migraine days from baseline across months 5 and 6, but neither the onabotA 155 U nor the 195 U group demonstrated a statistically significant improvement compared to the placebo group.
  • Adverse events in the trial were consistent with previous findings for onabotA in chronic migraine and were generally mild to moderate in severity.
  • The research highlights the need for further understanding of the pathophysiological differences between episodic and chronic migraine and whether onabotA may be effective in a subset of episodic migraine patients.
  • Andrew M. Blumenfeld, Patricia Pozo-Rosich, Richard B. Lipton, Ronald E. DeGryse, Beibei Li, Aubrey M. Adams, Thu Nguyen, Lynn James, and Mitchell F. Brin were involved in the research.

Statistics:

  • 775 patients were included in the PRECLUDE trial.
  • The study had a 24-week double-blind phase and a 24-week open-label extension phase.
  • Neither onabotA 155 U nor 195 U group demonstrated a statistically significant improvement compared to the placebo group.
  • The primary endpoint was the change in the frequency of monthly migraine days from baseline across months 5 and 6.

Sources:

  • Cephalalgia (2025;45(10):3331024251370769)
  • Sage Publications Ltd (1 Olivers Yard, 55 City Road, London EC1Y 1SP, England)
  • NewsRx (Study Results from Andrew M. Blumenfeld and Colleagues Broaden Understanding of Headache (OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled ...))